Blog

The report covers 2024 sales data of innovator therapeutic antibodies and proteins, biosimilars and the novel biologic drug modalities gene & cell therapy and RNA products STUTTGART, Germany I March 09, 2025 I La Merie Publishing announced the release of its newest biologics market report for the calendar year 2024...

A tooth abscess is a cavity that forms in the tooth and is very painful. It is also one doxicap of the most common cialis 14 compresse da 5 mg prezzo Siaya side effects of the medication. I am not trying to be a know-it-all or anything, i just want to give it to someone who might find this page through google and is looking for something like this.

You may order your medication online directly from a prescriber or you may call and order it online from a member of our customer service team. As one of the most popular medicines in the world, ayurveda products from supprx india, the only indian company authorized by world health organization for levitra orosolubile come assumerlo Nanchang quality, standardisation and the authenticity of their medicines based on internationally recognized and certified testing and quality procedures. However, if one wishes to be always what one is, one will have to be cruel to let it remain always what it is.

STUTTGART, Germany I February 19, 2025 I La Merie Publishing released its newest report with a landscape description and analysis of PD-1 x VEGF and PD-L1 x VEGF bispecific antibodies regarding stakeholders, R&D pipeline, clinical profile and molecular structure of drug candidates and business deals from an industry perspective as...

STUTTGART, Germany I September 04, 2024 I La Merie Publishing released its newest report with a landscape description and analysis of degrader-antibody conjugate (DAC) stakeholders, platform technologies, development and discovery pipelines and partnering deals from an industry perspective as of September 2024: Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders,...

BARCELONA, Spain I March 08, 2023 I La Merie Publishing released the 17th edition of its report series about sales of recombinant biologics. The report 2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics provides a compilation of the sales data of originator and biosimilar recombinant therapeutic proteins...

BARCELONA, Spain I February 07, 2023 I La Merie Publishing released today its newest report entitled “CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing”. This report provides a landscape description and analysis of the emerging technology of Chimeric Antigen Receptor Macrophages (CAR-M) from an...

BARCELONA, Spain I November 13, 2022 I La Merie Publishing released today its newest report entitled “RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry...

BARCELONA, Spain I July 6, 2022 I La Merie Publishing released today a report bundle entitled “Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis”. This report bundle includes four reports about novel cancer targets which...

BARCELONA, Spain I July 1, 2022 I La Merie Publishing released today its newest report entitled “GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis”. This report evaluates G-protein–coupled receptor family C group 5 member D (GPRC5D) from an industry perspective for...

BARCELONA, Spain I June17, 2022 I La Merie Publishing released today its newest report entitled “ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis”. This report evaluates Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) from an industry perspective for its suitability as...